DOCSLIB.ORG

Nnvol23n1.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nnvol23n1.Pdf www.drugabuse.gov Volume 23, Number 1 U.S. Department of Health and Human Services | National Institutes of Health Behavior Game Played in ALSO IN THIS ISSUE Primary Grades Reduces Later Research Findings 8 Young Opioid Abusers Drug-Related Problems Benefit From Extended Buprenorphine-Naloxone Treatment Positive effects are most pronounced in disruptive boys. 10 Vouchers Boost Smoking Abstinence During Pregnancy BY NIDA NOTES STAFF in the Good Behavior Game (GBG), a classroom 11 Attention to Bipolar activity designed to inculcate appropriate behav- Disorder Strengthens Substance Abuse warding smiley-face stickers to ior during children’s first 2 years in school. Treatment teams of first-graders in Balti- “The GBG gives teachers an effective method more for the good behavior of the of managing behavior in the classroom and of Director’s Perspective 2 Helping Doctors Become individual team members greatly teaching children how to be students,” says Dr. First Responders to Aincreased the likelihood that the students would Sheppard Kellam of the American Institutes for Substance Abuse experience an adolescence free of substance Research in Washington, D.C. Research in Brief abuse and dependence. Teachers gave out the Dr. Kellam and colleagues began the longitu- 3 • Some Teens Reporting stickers and other token rewards and penalties dinal study of the GBG while at Johns Hopkins Nonmedical Use of Prescriptions Develop University in close partner- Dependence Disorders ship with the Baltimore City • Peer Interaction AS THE TWIG IS BENT Young adults who had played the Good Enhances Adolescent Rats’ Behavior Game in first and second grade were less likely to smoke ciga- Public School System. Dr. Drug Reward • Stroop rettesr o abuse drugs than those who hadn’t played the game. Males Kellam suggests that the Test Identifies Patients whose first-grade teachers identified them as aggressive and disruptive at Risk for Treatment benefited the most. activity produces a broad Dropout • Genetic Overlap spectrum of long-term ben- Between Substance Abuse and Bipolar Disorder efits by steering 5- and 6-year- Good Behavior Game Control 4 NIDA at Work olds away from aggressive and 70% NIDA’s Genetics disruptive behaviors, which Workgroup Directs Search for Genes That Influence 60% have long been recognized as precursors of many negative Addiction 50% adolescent and adult out- Bulletin Board comes. The study found that 14 • Dr. Phil Skolnick Now 40% Leads NIDA’s Medications the GBG was protective not Development Efforts only against substance abuse • How-To Guides Provide 30% Tips for Publishing and dependence but also Addiction-Related Articles 20% against teenage delinquency, • Dr. James A. Inciardi antisocial personality disor- (1939–2009) 10% der, and suicide attempts. Tearoff 15 Reality Videos Bring NIDA Prevalence of Problem Behaviors at Age 19–21 Prevalence of Problem Behaviors at Scientists to Web Site for 0 HOW TO PLAY THE GAME Drug Abuse Smoking Drug Abuse Smoking Drug Abuse Smoking Teens Teachers first set the rules All Females All Males Males Disruptive in First Grade of the game, presenting a list 16 What the Numbers Say [ Continued on page 6 ] NIDA Notes | Volume 23, Number 1 1 ■ DIRECTOR’S PERSPECTIVE By NORA D. VOLKOW, M.D., NIDA Director NIDA Notes EDITOR David Anderson Public Health Advisor, Office of Science Policy and Communications, National Institute on Drug Abuse DEPUTY EDITOR Julie Ann Miller, Ph.D. RTI International Helping Doctors Become First MANAGING EDITOR Andrew Keegan RTI International Responders to Substance Abuse SENIOR SCIENCE WRITER Lori Whitten, Ph.D. RTI International very day, the Nation’s primary care and family physicians see patients whose use SCIENCE WRITER Laura Bonetta, Ph.D. of addictive substances causes them problems. Too often, physicians cannot RTI International appropriately diagnose and treat those problems because the patients do not ASSOCIATE EDITOR disclose their substance abuse. Patients’ fear of revealing sensitive and poten- Debra P. Davis RTI International tially stigmatizing information and the omission of the topic of addiction in many physi- E DESIGN/LAYOUT cian training programs lead to suboptimal medical care. Maggie Bray To remedy this situation, NIDA has developed RTI International NIDAMED, the Institute’s first comprehensive EDITORIAL BOARD David Anderson, Chair; Public Physicians’ Outreach Initiative. NIDAMED aims Health Advisor, Office of Science Policy to integrate screening and treatment for the disease of addiction with mainstream medi- and Communications cal care. A toolkit developed by NIDAMED guides doctors in assessing a patient’s risk Nicolette Borek, Ph.D., Research Psychologist, Division of Clinical Neuroscience of developing an addiction problem, advising patients on the health effects of substance and Behavioral Research abuse and, if needed, arranging a referral to specialty care. The toolkit contains : J.C. Comolli, Public Health Advisor, Division of Pharmacotherapies and Medical ■ NIDA-Modified Alcohol, Smoking and Substance Involvement Screening Test Consequences of Drug Abuse (NM-ASSIST)—This evidence-based instrument, available on an interactive Web site Jennifer Elcano, M.A., Science Writer, or in print, guides clinicians through a brief screening interview about use of addictive Office of Science Policy and Communications Lynda Erinoff, Ph.D., Associate substances, including illicit drugs, prescription drugs taken for nonmedical purposes, Director, AIDS Research Program, Division tobacco, and alcohol. of Epidemiology, Services and Prevention Research ■ Clinician’s Resource Guide—This accompanying online guide presents clinicians Jacqueline Lloyd, Ph.D., Health Science with more detailed instructions, directions on how to access further information on Administrator, Division of Epidemiology, substance abuse, and comprehensive referral resources. Services and Prevention Research Marsha F. Lopez, Ph.D. , Health Science ■ Screening Tool Quick Reference Guide—This pocket-size resource summarizes the Administrator, Division of Epidemiology, screening tool, risk levels, and followup actions. Services and Prevention Research Gerald McLaughlin, Ph.D. , Chief, Grants ■ Patient Information Card—This postcard-size handout for physicians’ waiting Review Branch, Office of Extramural Affairs rooms encourages patients to “Tell Your Doctors About All the Drugs You Use” to get Mary Ellen Michel, Ph.D., Deputy the best care and also offers Web links to more information. Director, Center for the Clinical Trials Network Ivan Montoya, M.D., M.P.H., Medical Another critical component of NIDAMED is outreach to medical students, residents, Officer, Division of Pharmacotherapies and and those who train them. Through a partnership with eight medical schools around Medical Consequences of Drug Abuse the country, NIDA’s Centers of Excellence for Physician Information provide innova- Mary Pfeiffer, Ph.D., Editor and Writer, Intramural Research Program tive, science-based curriculum resources on substance abuse, addiction, and their health Kenzie Preston, Ph.D., Chief, Clinical consequences. Pharmacology and Therapeutics Research Doctors can access the new tools at www.drugabuse.gov by clicking on the Branch Joni Rutter, Ph.D., Program Director, NIDAMED icon. The Institute also recently updated Principles of Drug Addiction Genetics and Molecular Neurobiology Research Treatment: A Research-Based Guide, which summarizes more than three decades of Branch, Division of Basic Neuroscience and Behavioral Research research. In addition, a poster that encourages patients to disclose their drug use is avail- Anna Staton, M.P.A., Public Health able by calling 1-877-NIDA-NIH. NIDA is collaborating with the U.S. Health Resources Analyst, Office of Science Policy and Communications and Services Administration, Food and Drug Administration, and New York City Health Cora Lee Wetherington, Ph.D., Department to place the poster in health clinics throughout the Nation. ■ Psychologist, Division of Basic Neuroscience and Behavioral Research This publication was produced and printed by RTI International, under Contract No. N01DA-4-1117 from the National Institute on Drug Abuse. 2 NIDA Notes | Volume 23, Number 1 ■ RESEARCH IN BRIEF Highlights of recently published NIDA-supported studies 56 days, on average, in the year include peer contact may more inhibited. In the Boston trial, under review, and those who closely mimic early stages of this difference—of about 30 were dependent on the drugs drug abuse, which typically seconds, on average—was 24 had used them for 87 days. occurs in a group setting percent greater among patients Girls were significantly more > Psychopharmacology 204(3):391- who dropped out than among likely to become dependent 402, 2009. those who completed therapy. on nonprescribed pain reliev- > Drug and Alcohol Dependence 96(3):202-212, 2008. > Neuropsychopharmacology Some Teens Reporting ers than boys, a finding that 33(4):827-836, 2008. Nonmedical Use of the researchers suggest may Prescriptions Develop reflect, in part, girls’ greater Genetic Overlap Disorders tendency to share prescribed Between Substance Dr. Li-Tzy Wu and colleagues pain relievers with friends. Abuse and Bipolar at Duke University and the > Journal of the American Disorder Pacific Institute for Research Academy of Child and Adolescent According to a recent literature and Evaluation found that 1 Psychiatry 47(9):1020-1029, 2008. analysis by Dr. Ranga Krishnan percent of the 36,992 respon- of Duke University Medi- dents
Load more

Recommended publications
  • BMC Pharmacology Biomed Central
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Springer - Publisher Connector BMC Pharmacology BioMed Central Research article Open Access Pharmacological Properties of DOV 315,090, an ocinaplon metabolite Dmytro Berezhnoy†1, Maria C Gravielle†1, Scott Downing1, Emmanuel Kostakis1, Anthony S Basile2, Phil Skolnick2, Terrell T Gibbs1 and David H Farb*1 Address: 1Laboratory of Molecular Neurobiology, Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, 715 Albany St., Boston, MA 02118, USA and 2DOV Pharmaceutical, Inc, 150 Pierce St., Somerset, NJ 08873-4185, USA Email: Dmytro Berezhnoy - [email protected]; Maria C Gravielle - [email protected]; Scott Downing - [email protected]; Emmanuel Kostakis - [email protected]; Anthony S Basile - [email protected]; Phil Skolnick - [email protected]; Terrell T Gibbs - [email protected]; David H Farb* - [email protected] * Corresponding author †Equal contributors Published: 13 June 2008 Received: 20 December 2007 Accepted: 13 June 2008 BMC Pharmacology 2008, 8:11 doi:10.1186/1471-2210-8-11 This article is available from: http://www.biomedcentral.com/1471-2210/8/11 © 2008 Berezhnoy et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background: Compounds targeting the benzodiazepine binding site of the GABAA-R are widely prescribed for the treatment of anxiety disorders, epilepsy, and insomnia as well as for pre- anesthetic sedation and muscle relaxation. It has been hypothesized that these various pharmacological effects are mediated by different GABAA-R subtypes.
    [Show full text]
  • Failed Trials for Central Nervous System Disorders Do Not Necessarily
    CORRESPONDENCE LINK TO ORIGINAL ARTICLE funding often outweighs the efforts required to rigorously challenge the novel findings; Failed trials for central nervous system thus, verification in an independent laboratory is unlikely. disorders do not necessarily invalidate As the costs of clinical studies are so much higher than those of preclinical development, preclinical models and drug targets one might assume that pharmaceutical com- panies would conduct robust replications of key findings. This is indeed the case during Anton Bespalov, Thomas Steckler, Bruce Altevogt, Elena Koustova, Phil Skolnick, lead optimization, candidate selection, test- Daniel Deaver, Mark J. Millan, Jesper F. Bastlund, Dario Doller, Jeffrey Witkin, ing different administration routes and the Paul Moser, Patricio O’Donnell, Ulrich Ebert, Mark A. Geyer, Eric Prinssen, use of primary preclinical disease models. Theresa Ballard and Malcolm Macleod However, this is far less common for stud- ies in the more complex disease models that are used in late stages of development and A recent article identified five key technical modest effects on survival. Numerous other are potentially more relevant for predicting determinants that make substantial contribu- drug candidates have reported efficacy in a clinical efficacy. tions to the outcome of drug R&D projects superoxide dismutase 1 (SOD1) mouse model In general, the rigorousness with which (Lessons learned from the fate of AstraZeneca’s of ALS (one of the common animal models preclinical data is obtained — and the result- drug pipeline: a five-dimensional framework. for this disease), but none of these candidates ing robustness of the data — is quite low; Nat. Rev. Drug Discov. 13, 419–431 (2014))1.
    [Show full text]
  • The Opioid Epidemic: Crisis and Solutions
    PA58CH09-Skolnick ARI 18 November 2017 9:40 Annual Review of Pharmacology and Toxicology The Opioid Epidemic: Crisis and Solutions Phil Skolnick Opiant Pharmaceuticals, Santa Monica, California 09401, USA; email: [email protected] Annu. Rev. Pharmacol. Toxicol. 2018. 58:143–59 Keywords First published as a Review in Advance on heroin, overdose, naloxone, vaccines, medication-assisted therapies, pain October 2, 2017 The Annual Review of Pharmacology and Toxicology Abstract by [email protected] on 01/16/18. For personal use only. is online at pharmtox.annualreviews.org The widespread abuse of prescription opioids and a dramatic increase in https://doi.org/10.1146/annurev-pharmtox- the availability of illicit opioids have created what is commonly referred to 010617-052534 as the opioid epidemic. The magnitude of this epidemic is startling: About Copyright c 2018 by Annual Reviews. 4% of the adult US population misuses prescription opioids, and in 2015, Annu. Rev. Pharmacol. Toxicol. 2018.58:143-159. Downloaded from www.annualreviews.org All rights reserved more than 33,000 deaths were attributable to overdose with licit and illicit opioids. Increasing the availability of medication-assisted treatments (such as buprenorphine and naltrexone), the use of abuse-deterrent formulations, and ANNUAL REVIEWS Further the adoption of US Centers for Disease Control and Prevention prescribing Click here to view this article's guidelines all constitute short-term approaches to quell this epidemic. How- online features: • Download figures as PPT slides ever, with more than 125 million Americans suffering from either acute or • Navigate linked references • Download citations chronic pain, the development of effective alternatives to opioids, enabled at • Explore related articles • Search keywords least in part by a fuller understanding of the neurobiological bases of pain, offers the best long-term solution for controlling and ultimately eradicating this epidemic.
    [Show full text]
  • Bfm:978-3-0348-8470-9/1.Pdf
    Milestones in Drug Therapy MDT Series Editors Prof. Dr. Michael J. Pamham Prof. Dr. J. Bruinvels PLIVA INFARM Research Institute Sweelincklaan 75 Prilaz baruna Filipovica 25 NL-3723 JC Bilthoven 10000 Zagreb The Netherlands Croatia Anxiolytics Edited by M. Briley and D. Nutt Springer Basel AG Editors Dr. Mike Briley Professor David Nutt Institut de Recherche Pierre Fabre University of Bristol Parc Industriei de la Chartreuse Psychophannacology Unit 8 I 100 Castres School of Medical Science France University Walk Bristol BS8 ITD UK Library of Congress Cataloging-in-Publication Data Anxiolytics / edited by M. Briley and D. NuU, p. cm - Milestones in drug therapy) lncludes bibliographical references and index. ISBN 978-3-0348-9581-1 ISBN 978-3-0348-8470-9 (eBook) DOI 10.1007/978-3-0348-8470-9 1. Tranquilizing drugs. 1. Briley, M. II. Nutt, David J., 1951- III. Series. RM333 A582 2000 615'.7882--{jc2I 00-033748 Deutsche Bibliothek Cataloging-in-Publication Data Anxiolytics / ed. by M. Briley and D. Nutt. - Basel ; Boston; Berlin: Birkhiiuser, 2000 (Milestones in drug therapy) ISBN 978-3-0348-9581-1 ISBN 978-3-0348-9581-1 The publisher and editor can give no guarantee for the infonnation an drug dosage and administration contained in this publication. The respective user must check its accuracy by consulting other sources of reference in each individual case. The use of registered names, trademarks etc. in this publication, even if not identified as such, does not imply that they are exempt from the relevant protective laws aud regulations or free for general use. This work is subject to copyright.
    [Show full text]
  • Beyond Monoamine-Based Therapies: Clues to New Approaches
    Beyond Monoamine-Based Therapies: New Approaches Beyond Monoamine-Based Therapies: Clues to New Approaches Phil Skolnick, Ph.D. Advances in antidepressant therapy have resulted in agents with fewer serious side effects than, for example, nonselective monoamine oxidase inhibitors and tricyclic antidepressants. Nonetheless, these © Copyrightnewer agents are far from 2002 the ideal. Physicians Many of the drawbacks Postgraduate associated with these newer Press, agents—slow Inc. onset, low rate of response, and low rate of remission—are likely to be mechanism related. In order to overcome these problems, researchers must either improve upon these traditional, biogenic amine– based mechanisms or explore nontraditional mechanisms. Strategies for improving biogenic amine– based antidepressants include the so-called serotonin augmentation strategy and the broad spectrum agent that simultaneously blocks reuptake at the serotonin, norepinephrine, and dopamine transport- ers. Two nontraditional approaches employ modulation of glutamate receptor function. At face value, these glutamate-based approaches (N-methyl-D-aspartate [NMDA] antagonists and α-amino-3- hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA] receptor potentiators) appear diametrically opposed. However, these 2 mechanisms may ultimately impact similar cellular endpoints. (J Clin Psychiatry 2002;63[suppl 2]:19–23) One personal copy may be printed dvances in antidepressant treatment have resulted in generally termed serotonin augmentation. This strategy is Aagents that are safer and easier to use than, for based on the hypothesis that the delayed onset of seroto- example, nonselective irreversible monoamine oxidase in- nin-based agents (including selective serotonin reuptake hibitors (MAOIs) and tricyclics (TCAs). These newer inhibitors [SSRIs] and TCAs such as imipramine) is agents are far from ideal.
    [Show full text]
  • Virginia Drug Discovery Consortium Virginiabrainrx: a Symposium on Drug Discovery for the Brain
    Virginia Drug Discovery Consortium VirginiaBrainRx: A Symposium on Drug Discovery for the Brain May 23 - 24, 2016 Omni Richmond Hotel Richmond, Virginia Welcome letter May 23, 2016 Dear Symposium Participants: On behalf of the Organizing Committee, it is my great pleasure to welcome you to Richmond and to the VirginiaBrainRx Symposium. This Symposium includes five keynote lectures and several invited lectures from distinguished scientists, and also features poster presentations by scientists from around the Commonwealth. One of the major purposes of this Symposium is to provide networking opportunities that could foster new inter-university and public-private collaborative projects in brain drug-discovery. The NIH Roadmap for Research states “The scale and complexity of today’s … research problems increasingly demand that scientists move beyond the confines of their own discipline and explore new organizational models for team science….…”, and this Symposium has the goal of furthering such collaborations, especially when it comes to the discovery, development, and delivery of drugs to treat brain illness. The organizers hope that everyone will take advantage of the poster sessions and social times to meet new colleagues and to explore new collaborations. This Symposium is the first major public project of the fledgling irginia“V Drug Discovery Consortium.” This Consortium has the aim of fostering collaborative drug discovery research in all disease areas between Virginia’s universities and the pharmaceutical and biotech industries, and it plans to sponsor regular Symposia on different aspects of drug discovery, with the next one tentatively scheduled for Spring 2017. A short questionnaire is included in your registration materials, and I hope that you will take the time to complete this on Tuesday so as to guide the organizers in planning future Symposia.
    [Show full text]
  • Milestones in Drug Therapy
    Milestones in Drug Therapy Series Editors Michael J. Parnham, Director of Science & Technology, MediMlijeko d.o.o., Zagreb, Croatia Jacques Bruinvels, Bilthoven, The Netherlands Advisory Board J.C. Buckingham, Imperial College School of Medicine, London, UK R.J. Flower, The William Harvey Research Institute, London, UK A.G. Herman, Universiteit Antwerpen, Antwerp, Belgium P. Skolnick, National Institute on Drug Abuse, Bethesda, MD, USA For further volumes: http.//www.springer.com/series/4991 . Phil Skolnick Editor Glutamate-based Therapies for Psychiatric Disorders Volume Editor Phil Skolnick, Ph.D., D.Sc. (hon.) Director, Division of Pharmacotherapies & Medical Consequences of Drug Abuse National Institute on Drug Abuse 6001 Executive Boulevard Bethesda, MD 20892 USA [email protected] Series Editors Prof. Dr. Michael J. Parnham Director of Science & Technology MediMlijeko d.o.o. Pozarinje 7 HR-10000 Zagreb Croatia Prof. Dr. Jaques Bruinvels Sweelincklaan 75 NL-3723 JC Bilthoven The Netherlands ISBN 978-3-0346-0240-2 e-ISBN 978-3-0346-0241-9 DOI 10.1007/978-3-0346-0241-9 Library of Congress Control Number: 2010935790 # Springer Basel AG 2010 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcast- ing, reproduction on microfilms or in other ways, and storage in data banks. For any kind of use, permission of the copyright owner must be obtained. The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protec- tive laws and regulations and therefore free for general use.
    [Show full text]
  • ASPET Preliminary Program for Experimental Biology 2003
    ASPET Preliminary Program for Experimental Biology 2003 Symposia Saturday Morning Inverse agonism: translation to in vivo function Chairs: James H. Woods and Richard Neubig Current status of inverse agonism as a pharmacological and therapeutic tool. Graeme Milligan, Univ. of Glasgow, Scotland Delta-opioid inverse agonists. Chris J. Evans, UCLA Inverse agonists in chemokine receptors. M.R. Brann, Acadia Pharmaceut. Inverse agonists and competitive antagonists in benzodiazepine dependent monkeys. Charles P. France, Univ. of Texas Hlth. Sci. Ctr., San Antonio Actions of hallucinogens and atypical antipsychotic drugs at serotonin receptors Chairs: Bryan L. Roth and David R. Sibley Atomic and molecular mechanisms of 5-HT2A receptor activation, targeting and trafficking. Bryan L. Roth, Case Western Reserve Univ. Med. Sch. RNA editing and genomic polymorphisms: relevance for schizophrenia, atypical antipsychotics and hallucinogens. Elaine Sanders-Bush, Vanderbilt Univ. Med. Sch. Functional roles of 5-HT2A receptors in the prefrontal cortex. Rodrigo Andrade, Wayne State Univ. Med. Sch. 5-HT2A receptors in psychosis and antipsychotic treatments: insights from knockout mice. Jay Gingrich, Columbia Univ. Serotonin 2C receptor distribution in the ventral tegmental area. Marcy J. Bubar, Univ. of Texas Med. Br. at Galveston (Abstract 3105) A pharmacology core curriculum: to be or not to be Chairs: Patricia B. Williams and Gregory D. Fink Introduction: More than facts: knowledge, skills and attitudes. Patricia B. Williams, Eastern Virginia Med. Sch. The knowledge objectives and essential drug list. Gary Rosenfeld, Univ. of Texas-Houston Med. Sch. A view from the top: a chairman speaks. Kenneth E. Moore, Michigan State Univ. Teaching medical school pharmacology in the 21st Century – can a core knowledge base be defined? Eric P.
    [Show full text]
  • Resource List
    National Institute of OPIOIDS AND THE WORKPLACE: Environmental Health Sciences Worker Training Program PREVENTION AND RESPONSE RESOURCE LIST Agency, Industry, Labor Union Information Federal Agency ■ National Institute of Environmental Health Sciences (NIEHS), National Clearinghouse for Worker Safety and Health Training. Illicit Drug Exposure. This page has links to the NIEHS “Prevention of Occupational Exposure to Fentanyl and Other Opioids” awareness-level training tool. https://tools.niehs.nih.gov/wetp/index.cfm?id=2562 ■ National Institute for Occupational Safety and Health (NIOSH). Opioids in the Workplace. This page has links to NIOSH field studies, guidelines, research, and data. https://www.cdc.gov/niosh/topics/opioids/default.html ■ National Institutes of Health (NIH), U.S. National Library of Medicine (NLM). Opioid Addiction and Treatment Health Information Resources. This page contains comprehensive and organized links to government information. https://envirotoxinfo.nlm.nih.gov/opiate-addiction-and-human-health.html#a2 Industry ■ 3M. Beyond Responding to Drug Overdoses: Keeping You Safe from Fentanyl. https://multimedia.3m.com/mws/media/1383737O/fentanyl-3m-whitepaper.pdf ■ Construction Industry Alliance for Suicide Prevention. http://www.cfma.org/news/content.cfm?ItemNumber=4570 ■ Dupont. Fentanyl and Other Opioids. http://www.dupont.com/products-and-services/personal-protective-equipment/chemical-protective- garments/articles/protection-against-fentanyl-opiods.html ■ Harris P. 2017. The opioid crisis and workplace safety. Cremation Association of North America Blog, 14 September. http://www.cremationassociation.org/blogpost/776820/284743/The-Opioid-Crisis-and-Workplace- Safety 1 Opioids and the Workplace National Institute of OPIOIDS AND THE WORKPLACE: Environmental Health Sciences Worker Training Program PREVENTION AND RESPONSE Labor Union ■ Association of Union Contractors.
    [Show full text]
  • Pharmacology of Ibogaine and Ibogaine-Related Alkaloids
    The Ibogaine Dossier. Pharmacology of Ibogaine https://ibogainedossier.com/alkaloids.html The Ibogaine Dossier Main | Search | Science | Opinion | Literature | Links | Treatment | Bookshop | Feedback Pharmacology of Ibogaine and Ibogaine-Related Alkaloids Piotr Popik , Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, NYU Conference on Ibogaine Poland Nov 5-6, 1999 and Phil Skolnick , Neuroscience Discovery, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA Appeared as Chapter #3, in "THE ALKALOIDS", Vol.52, pp. 197-231. 1998, San Diego, USA. ISBN 0-12-469552-3. Edited by G.A. Cordell. © 1998 by Academic Press Order The Alkaloids, Vol. 52 T. iboga roots Ibogaine is extracted from the bark of the root CONTENT I. INTRODUCTION II. HISTORICAL OVERVIEW. III. CHEMICAL STRUCTURE AND PROPERTIES. IV. PHARMACOKINETICS. V. GENERAL PHARMACOLOGICAL ACTIONS. A. Animal Studies 1. Locomotor activity. a. Effects on locomotor activity induced by other drugs 2. Tremor. 3. Anxiety and fear. 4. Effects on self-administration of other drugs. 5. Effects on drug dependence. 6. Pain and analgesia. 7. Aggression. 8. Interoceptive properties. 9. Reinforcing effects. 10. Effects on learning and memory. 11. Cardiovascular actions. B. Human Studies. VI. LETHALITY AND NEUROTOXIC EFFECTS. VII. EFFECTS ON SPECIFIC NEUROTRANSMITTER SYSTEMS A. Ibogaine Effects on Dopaminergic Systems. 1. Dopaminergic effects: Pharmacological Specificity. 2. Ibogaine alters the effects of abused drugs on dopaminergic systems. B. Opioid Systems C. Serotonergic Systems. D. Calcium Regulation. 1 of 30 1/20/2019 6:13 AM The Ibogaine Dossier. Pharmacology of Ibogaine https://ibogainedossier.com/alkaloids.html E. Cholinergic Systems. F. Gamma-Aminobutyric Acidergic [GABAergic] Systems. G.
    [Show full text]
  • Elsevier Editorial System(Tm) for Trends in Pharmacological Sciences Manuscript Draft
    Elsevier Editorial System(tm) for Trends in Pharmacological Sciences Manuscript Draft Manuscript Number: TIPS-D-09-00098R1 Title: Glutamate Based Antidepressants: 20 Years On Article Type: Opinion Keywords: N-methyl-D-aspartate receptors; NMDA antagonists; depression; antidepressants; glutamate; ionotropic glutamate receptors; metabotropic glutamate receptors Corresponding Author: Dr Phil Skolnick, Corresponding Author's Institution: New York University Langone Medical Center First Author: Phil Skolnick Order of Authors: Phil Skolnick; Piotr Popik, M.D., Ph.D.; Ramon Trullas, Ph.D. Abstract: Depression is a chronic, recurring illness that affects more than 120 million people worldwide. Drugs increasing the synaptic availability of serotonin and norepinephrine (biogenic amine-based agents) have been used to treat depression for more than 50 years. However, significant symptom improvement requires ≥2-4 weeks of treatment, and a first course of therapy provides symptom relief to only 60-65% of patients. Roche and Evotec recently announced plans to develop N- methyl-D-aspartate (NMDA) receptor antagonists targeting the NR2B subtype for treatment resistant depression. This announcement closely follows a report that another NR2B antagonist, traxoprodil (CP 101,606), is antidepressant in patients unresponsive to a serotonin selective reuptake inhibitor (SSRI) as well as reports of rapid and sustained antidepressant effects following a single injection of the NMDA antagonist, ketamine. Here we describe evidence that glutamate-based therapies may represent an effective alternative to biogenic-amine based agents for depression, and provide perspectives on developing these agents. Cover letter Department of Behavioral Neuroscience and Drug Development tel: (+48+12) 6623375, fax: (+48+12) 6374500, e-mail: [email protected] Kraków, August 30, 2009 Dr.
    [Show full text]
  • Ketamine for Treatment-Resistant Depression Sanjay J
    Ketamine for Treatment-Resistant Depression Sanjay J. Mathew • Carlos A. Zarate Jr. Editors Ketamine for Treatment- Resistant Depression The First Decade of Progress Editors Sanjay J. Mathew Carlos A. Zarate Jr. Psychiatry and Behavioral Sciences Experimental Therapeutics and Baylor College of Medicine Pathophysiology Branch Michael E. Debakey VA Medical Center National Institute of Mental Health Houston , Texas National Institutes of Health USA Bethesda , Maryland USA ISBN 978-3-319-42923-6 ISBN 978-3-319-42925-0 (eBook) DOI 10.1007/978-3-319-42925-0 Library of Congress Control Number: 2016960037 © Springer International Publishing Switzerland (outside the USA) 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.
    [Show full text]